Benzinga

Benzinga

Benzinga

miércoles, agosto 26

Madrigal Pharmaceuticals Inc

MDGLNASDAQ
Trade with Public
Trade with Public
$512.16
0.190.04%
al cierre: Aug 24, 5:00 PM EST
$512.16
0.190.04%
Premercado: 4:00 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Madrigal Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Madrigal Pharmaceuticals (MDGL).

Price Target Range — 13 Quarters

Analyst Consensus — 17 Analysts

2S.Buy
14Buy
1Hold
Consensus RatingBuy# Analysts17Avg. Consensus PT$616Upside to Avg. PT+20.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 4, 2026Wolfe ResearchAndy ChenUpgradePeer Perform→Outperform$605
Aug 3, 2026BarclaysEliana MerlePT CutOverweight$964→$962
More with Benzinga EdgeGet Access

Analyst Ratings News

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Analysts upgraded Replimune, Madrigal, BBB Foods, Palantir, and Fomento Economico. See other opinions and price targets for these stocks.
Avi Kapoor

PRO
Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target

Wolfe Research analyst Andy Chen upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Peer Perform to Outperform and announces $605 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962

Barclays analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and lowers the price target from $964 to $962.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587

Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $578 to $587.
Benzinga Newsdesk

PRO
Wells Fargo Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $685

Wells Fargo analyst Sadia Rahman initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight rating and announces Price Target of $685.
Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542

B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral and lowers the price target from $550 to $542.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved